Avid Bioservices Inc (CDMO): MDSC's : Auto-Immune Diseases : Type I D...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	85
Posts	12714
Boards Moderated	0
Alias Born	10/12/2010

biopharm

Re: biopharm post# 171376

Thursday, 04/03/2014 10:35:05 PM

Thursday, April 03, 2014 10:35:05 PM

MDSC's : Auto-Immune Diseases : Type I Diabetes

No wonder why a partnership can't be inked....

Mr King, hold on... don't sign just yet! We need $500M more to get more clinical trials initiated, I think I know what you mean by that "astronomical" word now.

Role of myeloid-derived suppressor cells in type 1 diabetes

Adoptive transfer of MDSCs reduced diabetes by 75% compared with control group

http://www.jimmunol.org/cgi/content/meeting_abstract/186/1_MeetingAbstracts/167.16

Does everyone realize how many hundreds of trials will be initiated with Bavituximab and PS targeting ? I am stunned at how afraid? analysts are for not taking the plunge and staying ahead of the curve.

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!